Valeant Pharmaceuticals (NYSE:VRX) has teamed up with Pershing Capital, which owns nearly 10% of Allergan (NYSE:AGN), in an effort to acquire the remaining 90% of the company. However, as Allergan looks to have an excellent growth runway ahead, there may be a number of companies interested in swooping in and acquiring the company ahead of Valeant.
In this segment from Tuesday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at the roller coaster ride that Allergan has been on recently, and discuss some of the most likely candidates that may potentially be interested in being Allergan's white knight and acquiring the company.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
David Williamson owns shares of Johnson & Johnson and Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson and Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.